Episode Details

Eli Lilly just pulled out of the 340B drug pricing program, citing concerns over how some hospitals are handling the discounts — a move that’s sending shockwaves through the healthcare system. These hospitals, especially safety-net providers serving low-income and uninsured patients, rely on those savings to keep care affordable. Since its 1992 launch, the 340B program has been a lifeline for rural and Medicaid-heavy facilities, but now the pharmaceutical industry is watching closely, wondering if this could become a trend. With big financial stakes and deep ethical questions, this decision could reshape how drugmakers and hospitals negotiate access to life-saving medications — and who ultimately pays the price.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/6ad7a6ddcb9e2724